Highlights KALA BIO, Inc.

Equities

KALA

US4831192020

Market Closed - Nasdaq Other stock markets 21:30:01 10/05/2024 BST			5-day change	1st Jan Change
6.9 ^USD	+2.79%		-1.53%	-1.43%

04-02	HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating	MT
03-29	KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
KALA BIO, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-29	CI
North American Morning Briefing : Stocks Struggle After New Records	03-22	DJ
North American Morning Briefing : Inflation -2-	03-15	DJ
KALA BIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
KALA BIO, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04/08/23	CI
Kala Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI
Kala Pharmaceuticals, Inc. Announces Positive Safety Update from Cohort 1 of Chase Phase 2B Clinical Trial Evaluating KPI-012 in Patients with PCED	27/03/23	CI
KALA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	03/03/23	AQ
Kala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	03/03/23	CI
Kala Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	03/03/23	CI
Kala Pharmaceuticals Receives FDA Nod for Phase 2 Testing of Cornea Treatment, Triggering $25 Million in New Funding	27/12/22	MT
Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED	27/12/22	CI
Hopes of China Easing COVID-19 Policy Lift Exchange-Traded Funds, US Stock Futures Premarket Tuesday	29/11/22	MT
Kala Pharmaceuticals Submits Investigational Drug Application for Corneal Defect Drug Candidate	29/11/22	MT
Kala Pharmaceuticals Launches $31 Million Private Placement	28/11/22	MT
KALA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	08/11/22	AQ
Kala Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	08/11/22	CI
KALA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	11/08/22	AQ
Kala Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/08/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights KALA BIO, Inc.

Equities

KALA

US4831192020

Highlights

Filters